摘要
核苷(酸)类似物治疗慢性乙型肝炎的停药问题一直是学者及患者关注的临床问题。在临床实践中,很多研究结果显示核苷(酸)类似物停药复发率较高。患者年龄、基线HBVDNA载量、药物巩固治疗时间以及HBsAg水平是核昔(酸)类似物停药复发的相关因素。此外,有关核昔(酸)类似物停药后的安全性及复发后再治疗的应答问题也有很多研究。现就以上几个方面的研究进展进行综述。
Withdrawal of nucleos(t)ide analogues in chronic hepatitis B patients has always been a clinical problem for scholars and patients. Many studies showed that the withdrawal of nucleos(t)ide analogues often leads to a high recurrence rate in clinical practice. The factors such as age, baseline HBV DNA load, time of drug consolidation therapy, and HBsAg level are associated with recurrence after withdrawal of nucleos(t)ide analogues. In addition~ there are many studies on safety after withdrawal of nucleos(t)ide analogues and response to retreatment after recurrence. This article reviews the research advances in the aspects mentioned above.
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2016年第9期704-707,共4页
Chinese Journal of Hepatology
关键词
肝炎
乙型
慢性
核苷(酸)类似物
停药
Hepatitis B, chronic
Nucleos(t)ide analogues
Off-treatment